Release date: 2024-08-07 10:31:57 Article From: Lucius Laos Recommended: 98
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) primarily for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
The indication for Exkivity is primarily focused on adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
This indication targets approximately 30% of EGFR mutation-positive populations in lung cancer, particularly those who do not respond well to standard therapy or who have progressed during and after platinum-based chemotherapy. Exkivity controls tumor progression by highly selectively targeting exon 20 insertion mutations in EGFR and human epidermal growth factor receptor 2 (HER2) and effectively inhibiting the growth and spread of cancer cells driven by these mutations.
Lucius Pharmaceutical Co., Ltd. is a pharmaceutical company in Laos that has been involved in the field of anti-cancer drugs in recent years.
According to the relevant regulations of drug production, generic drugs need to undergo rigorous review and testing before marketing to ensure that their quality, safety, and efficacy are comparable to those of the original drug. The generic drugs produced by Lucius Pharmaceuticals also need to pass the review of the relevant regulatory agencies before they are marketed, and the quality of their products is guaranteed to a certain extent.
Lucius Pharmaceuticals not only strictly adheres to GMP standards and internationally recognized standards in the production process, but also makes great efforts in product quality control. The company strictly follows the European and American pharmacopeia standards for quality testing and control of drugs to ensure that each batch of products meets the specified quality requirements.
Lucius Pharmaceuticals Limited excels in quality standards and certifications and has been recognized and certified by several national and international authorities. These certifications not only prove the company's production capacity and product quality but also lay a solid foundation for the company's future development.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: